Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease through percutaneous cardiovascular interventions.
Improving the quality of life and reducing sudden cardiac death by limiting the impact of heart rhythm disturbances.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
Optison , Sonovue  and Luminity  have all been assessed for improvement of endocardial border delineation (EBD) during echocardiography in patients with sub-optimal image quality during unenhanced studies. These studies involved hundreds of patients and demonstrated that all three agents increased length of EBD (during end-systole and end-diastole), caused effective left ventricular opacification (LVO) and were able to ‘salvage’ an otherwise non-diagnostic study. When compared against a first-generation contrast agent, a markedly lengthier duration of action was noted for all second-generation agents.
As a consequence of this improved EBD and LVO, contrast imaging allows accurate calculation of ventricular volumes and ejection fraction and is superior to non-contrast enhanced harmonic imaging. Numerous studies have demonstrated this [4-7] and, in a multi-centre and multi-modality imaging study, LV volumes and LV EF as assessed by contrast echocardiography were as accurate as cardiac MRI and had the least inter-observer variability of all tests evaluated . No trial has ever shown contrast echocardiography to be inferior to another modality for the assessment of LV EF and LV volumes.
A recent study  also demonstrated the beneficial cost impact of contrast use during resting transthoracic echocardiography studies. 632 patients with sub-optimal image quality received contrast (Definity) and, amongst other factors, management decisions were compared before and after contrast administration. The percentage of uninterpretable studies was dramatically reduced (11.7% to 0.3%), further diagnostic tests were avoided in 32% of patients, drug management was altered in 10% and a cost/benefit analysis yielded a cost saving of $122 per patient .
© 2017 European Society of Cardiology. All rights reserved